Cancer has historically been seen as a disease of mutations. New science dictates a different paradigm — it is e a disease of architecture.
For years, circulating cell-free DNA (cfDNA) has largely been viewed as simply a genomic tool — a way to measure tumor burden, detect mutations, or monitor minimal residual disease. But emerging research in tumor spatial biology and the tumor immune microenvironment (TIME) suggests cfDNA may represent something far more important: a circulating reflection into the tumor ecosystem.

Recent studies evaluating spatial ecotypes in metastatic colorectal cancer demonstrate that response to therapy is not simply determined by the number of immune cells present within a tumor. Instead, the response appears to depend on where and what those immune cells are, whether they can physically access tumor cells, and whether organized immune niches form. It is about space, timing, location, and cell communication.

This is a massive conceptual shift.

The problem in many “cold” tumors is not that the immune system is broken. The problem is that the immune system is structurally unaware or excluded.

In immune-excluded tumors, T cells become trapped within peripheral stromal compartments while recruited myeloid suppressor cells, T regulator cells, and tumor-associated macrophages engineer physical and biochemical barriers that block immune access. Meanwhile, inflamed tumors demonstrate spatial proximity between CD8+ T cells, antigen-presenting cells, and tumor cells — forming functional immune ecosystems capable of coordinated anti-tumor responses. Yet, even in inflamed tumors, the immune system is dysfunctional, impaired, and restrained.

What makes these findings particularly exciting is the emerging correlation between these spatial ecosystems and cfDNA dynamics.
This raises an important possibility: liquid biopsy may not simply reflect tumor burden — it may reflect tumor architecture.
Inflamed tumors undergoing active immune-mediated therapy may generate cfDNA signatures that differ markedly from those of immune-desert and immune-excluded tumors locked behind stromal barriers. In other words, the blood may contain a fingerprint of the tumor ecosystem itself.

This opens the door to a completely new future for precision oncology.

Imagine integrating:
• Spatial ecotype imaging
• AI-driven TIME analysis
• Serial cfDNA monitoring
• Intratumoral immune profiling to dynamically track the remodeling of the tumor microenvironment ecosystem in real time.

This is particularly relevant for intratumoral immunotherapy and ablative approaches such as Pulsed Electric Field (PEF), cryoablation, where the goal may not simply be tumor destruction, but rather re-engineering and reprogramming the spatial biology of the tumor microenvironment itself.

Perhaps the future of oncology is not simply activating the immune system.
Perhaps the future is reprogramming immune access.

Because in cancer biology:
Location > Relationship > Quantity.

Learn more at Pre-Scribed.com

Reference:

Choo, J., Zhao, J.J., Lau, M.C. et al. Spatial predictors of response to chemo-immunotherapy in microsatellite stable metastatic colorectal cancer. Nat Commun (2026). https://doi.org/10.1038/s41467-026-72204-2
Wang, C., Zheng, P., Wang, A. et al. CD300ld on pathologically activated neutrophils promotes tumor immune suppression by binding phosphatidylserine on CD8+ T cells.Nat Cancer (2026). https://doi.org/10.1038/s43018-026-01169-4.
Espinosa-Carrasco G, Chiu E, Scrivo A, Zumbo P, Dave A, Betel D, Kang SW, Jang HJ, Hellmann MD, Burt BM, Lee HS, Schietinger A. Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors. Cancer Cell. 2024 Jul 8;42(7):1202-1216.e8. doi: 10.1016/j.ccell.2024.05.025.